Natixis Investment Managers International’s Regeneron Pharmaceuticals REGN Stock Holding History

Natixis Investment Managers International’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,706	Closed	-$1.6M	–	415
2022 Q2	$1.6M	Sell	2,706 -643	-19%	-$418K	0.03%	166
2022 Q1	$2.34M	Buy	+3,349	New	+$2.12M	0.04%	115
2018 Q4	–	Sell	-3,815	Closed	-$1.54M	–	449
2018 Q3	$1.54M	Buy	3,815 +1,672	+78%	+$636K	0.07%	255
2018 Q2	$739K	Buy	2,143 +1,829	+582%	+$572K	0.04%	335
2018 Q1	$108K	Buy	+314	New	+$109K	0.01%	407
2017 Q4	–	Sell	-1,524	Closed	-$681K	–	319
2017 Q3	$681K	Hold	1,524	–	–	0.06%	222
2017 Q2	$749K	Hold	1,524	–	–	0.07%	235
2017 Q1	$591K	Buy	+1,524	New	+$565K	0.05%	233
2016 Q2	–	Sell	-370	Closed	-$133K	–	396
2016 Q1	$133K	Sell	370 -692	-65%	-$285K	0.02%	339
2015 Q4	$577K	Sell	1,062 -639	-38%	-$346K	0.07%	133
2015 Q3	$791K	Buy	1,701 +512	+43%	+$275K	0.11%	133
2015 Q2	$607K	Buy	+1,189	New	+$580K	0.07%	164

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Natixis Investment Managers International's REGN Position: Q3 2022 in Review

Natixis Investment Managers International sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 2,706 shares — an estimated $1.6M sold.

Natixis Investment Managers International first reported a position in REGN in Q2 2015 and held it in 12 quarters. The position peaked at $2.34M in Q1 2022. 1,081 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Natixis Investment Managers International reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Natixis Investment Managers International sold 2,706 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $1.6M.
Natixis Investment Managers International first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 12 quarters.
Natixis Investment Managers International's Regeneron Pharmaceuticals position peaked at $2.34M in Q1 2022.
1,081 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Natixis Investment Managers International's 13F filing for Q3 2022, filed 14 Nov 2022.